Key Takeaways
- • EQT initiates preliminary takeover discussions with Oxford BioMedica, a UK-based contract development and manufacturing organisation (CDMO) specialising in cell and gene therapy, after the Stockholm-listed private equity group submitted an unsolicited cash offer approach for all shares.
- • Oxford BioMedica shares rallied 15% on takeover speculation, reaching valuations in the region of £1 billion, with stock performance up more than one-third year-to-date, reflecting strong operational momentum.
- • Prior EQT proposals were rejected as undervaluing the company, signalling the board's confidence in Oxford BioMedica's growth trajectory and willingness to engage only at valuations reflecting future prospects.
- • Strong financial performance and strategic expansion underpin valuation strength: interim revenues grew 44% to £73 million ($98 million), contracted client orders doubled to £149 million, and the company completed a €15 million acquisition of ABL Europe in 2024 plus a £3.4 million North Carolina manufacturing facility acquisition.
- • Board has committed to "preliminary discussions to explore whether a proposal can be made at a level that the board would be minded to recommend," indicating openness to a transaction at appropriate pricing but no guarantee of deal completion.
Summary
Oxford BioMedica confirmed on June 5, 2026, that it has entered preliminary discussions with Swedish private equity group EQT regarding a potential cash takeover of the FTSE 250-listed company. The unsolicited approach marks a significant moment for the UK-based CDMO, which specialises in developing and manufacturing cell and gene therapy products. The company's board stated it is exploring whether EQT can formulate a proposal at a valuation level the board would recommend to shareholders, though no indicative offer price has been disclosed.
The announcement triggered immediate market enthusiasm, with Oxford BioMedica shares surging 15% on takeover speculation. The stock's strength reflects broader confidence in the company's market position and growth prospects. The company's current market valuation sits in the region of £1 billion. Notably, EQT has made previous unsolicited approaches to acquire Oxford BioMedica, both of which were rejected by the board as undervaluing the business and its future potential—a signal that management and shareholders remain bullish on standalone prospects.
Oxford BioMedica's operational performance has been robust, supporting its valuation posture. In interim results published in September 2025, revenues reached £73 million ($98 million), representing 44% year-on-year growth. Contracted client orders more than doubled to £149 million, reflecting strong demand visibility. The company has executed a deliberate US expansion strategy, including the €15 million acquisition of ABL Europe in 2024 and a subsequent £3.4 million purchase of a commercial-scale viral vector manufacturing facility in North Carolina, which was expected to become operational in the first quarter of 2026.
The strategic acquisitions and capacity investments position Oxford BioMedica favourably within the high-growth cell and gene therapy manufacturing sector, a dynamic that has attracted private equity interest. EQT's renewed interest suggests the firm recognises the company's market position and the attractive medium-term growth profile within the CGT CDMO space. However, the absence of a formal offer and the board's cautious language around "preliminary discussions" indicates negotiations remain early-stage, with significant valuation gaps potentially remaining between buyer expectations and seller requirements.
The announcement triggered immediate market enthusiasm, with Oxford BioMedica shares surging 15% on takeover speculation. The stock's strength reflects broader confidence in the company's market position and growth prospects. The company's current market valuation sits in the region of £1 billion. Notably, EQT has made previous unsolicited approaches to acquire Oxford BioMedica, both of which were rejected by the board as undervaluing the business and its future potential—a signal that management and shareholders remain bullish on standalone prospects.
Oxford BioMedica's operational performance has been robust, supporting its valuation posture. In interim results published in September 2025, revenues reached £73 million ($98 million), representing 44% year-on-year growth. Contracted client orders more than doubled to £149 million, reflecting strong demand visibility. The company has executed a deliberate US expansion strategy, including the €15 million acquisition of ABL Europe in 2024 and a subsequent £3.4 million purchase of a commercial-scale viral vector manufacturing facility in North Carolina, which was expected to become operational in the first quarter of 2026.
The strategic acquisitions and capacity investments position Oxford BioMedica favourably within the high-growth cell and gene therapy manufacturing sector, a dynamic that has attracted private equity interest. EQT's renewed interest suggests the firm recognises the company's market position and the attractive medium-term growth profile within the CGT CDMO space. However, the absence of a formal offer and the board's cautious language around "preliminary discussions" indicates negotiations remain early-stage, with significant valuation gaps potentially remaining between buyer expectations and seller requirements.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.